Trial Profile
Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 07 May 2014 New trial record